Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age

Cancer Letters

Volumn 197, Issue 1-2, 2003, Pages 11-17

  Berthold, F ^a   Hero, B ^a   Kremens, B ^b   Handgretinger, R ^c   Henze, G ^d   Schilling, F H ^e   Schrappe, M ^f   Simon, T ^a   Spix, C ^g  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e OLGAHOSPITAL   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g German Childhood Cancer Registry   (Germany)

Author keywords

Bone marrow; Chemotherapy; MYCN; Neuroblastoma; Risk factors; Survival analysis

Indexed keywords

BETA INTERFERON; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FERRITIN; GD 2 MONOCLONAL ANTIBODY; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; MONOCLONAL ANTIBODY; PAPAVERINE; PLATINUM; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE;

ADOLESCENT; AGE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INFILTRATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG DOSE REGIMEN; FERRITIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; METASTASIS; NEUROBLASTOMA; ONCOGENE; ONCOGENE MYCN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; SURVIVAL RATE; SURVIVAL TIME; TOXICITY;

EID: 0037767946     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00076-4     Document Type: Conference Paper

References (13)

1. de Bernadi B., Carli M., Casale F., Corciulo P., Di Montezemolo L.C., De Laurentis C., Bagnulo S., Brisigotti M., Marchese N., Garaventa A., Felici L., Lo Curto M., Viscoli C., Tamaro P., Rogers D., Boni L., Dini G., Bruzii P. Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: two studies by the Italian cooperative group for neuroblastoma. J. Clin. Oncol. 10:1992;1870-1878.
2. Kaneko M., Tsuchida Y., Uchino J., Takeda T., Iwafuchi M., Ohnuma N., Mugishima H., Yokoyama J., Nishihira H., Nakada K., Sasaki S., Sawada T., Kawa K., Nagahara N., Suita S., Sawaguchi S. Treatment results of advanced neuroblastoma with the first Japanese study group protocol. J. Pediatr. Hematol. 21:1999;190-197.
3. Matthay K.K., Castleberry R.P. Treatment of advanced neuroblastoma: the US experience. Brodeur G.M., Sawada T., Tsuchida Y., Voûte P.A. Neuroblastoma. 2000;417-436 Elsevier Science, Amsterdam.
4. Castel V., Canete A., Navarro S., Garcia-Miguel P., Meleto C., Acha T., Navajas A., Badal M.D. Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med. Pediatr. Oncol. 27:2001;537-542.
5. Tsuchida Y., Kaneko M. Treatment of advanced neuroblastoma: the Japanese experience. Brodeur G.M., Sawada T., Tsuchida Y., Voûte P.A. Neuroblastoma. 2000;453-469 Elsevier Science, Amsterdam.
6. Berthold F., Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs. 59:2000;1261-1277.
7. Berthold F., Burdach S., Kremens B., Lampert F., Niethammer D., Riehm H., Ritter J., Treuner J., Utsch S., Zieschang J. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience. Klin. Pediatr. 202:1990;262-269.
8. Brodeur G.M., Pritchard J., Berthold F., Carlsen N., Castel V., Castleberry R.P., de Bernardi B., Evans A.E., Favrot M., Hedborg F., Kaneko M., Kemshead J., Lampert F., Lee R., Look T., Pearson A.D., Philip T., Roald B., Sawada T., Seeger R.C., Tsuchida Y., Voûte P.A. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J. Clin. Oncol. 11:1993;1466-1477.
9. Schilling F.H., Spix C., Berthold F., Erttmann R., Fehse N., Hero B., Klein G., Sander J., Schwarz K., Treuner J., Zorn U., Michaelis J. Neuroblastoma screening at one year of age. N. Engl. J. Med. 346:2002;1047-1053.
10. Berthold F., Trechow R., Utsch S., Zieschang J. Prognostic factors in metastatic neuroblastoma. Am. J. Pediatr. Hematol. Oncol. 14:1992;207-215.
11. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. N. Engl. J. Med. 341:1999;1165-1173.
12. Frappaz D., Michon J., Coze C., Berger C., Plouvier E., Lasset C., Bernard F.L., Stephan J.L., Bouffet E., Buclon M., Comaret V., Fourquet A., Philip T., Zucker J.M. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastoma in children older than 1 year at diagnosis. J. Clin. Oncol. 18:2000;468-476.
13. Burkardt-Hammer T., Spix C., Brenner H., Kaatsch P., Berthold F., Hero B., Michaelis J. Long-term survival of children with neuroblastoma prior to the neuroblastoma screening project in Germany. Med. Pediatr. Oncol. 39:2002;156-162.